Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit

Combination Antifungal Therapy for Invasive Aspergillosis

(2015) Kieren A. Marr et al.   ANNALS OF INTERNAL MEDICINE

Effectiveness of Primary Anti-Aspergillus Prophylaxis during Remission Induction Chemotherapy of Acute Myeloid Leukemia

(2014) M. Z. R. Gomes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study

(2014) N. Lerolle et al.   CLINICAL MICROBIOLOGY AND INFECTION

Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand

(2014) S. J. van Hal et al.   INTERNAL MEDICINE JOURNAL

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014

(2014) S. Fleming et al.   INTERNAL MEDICINE JOURNAL

Incidence Density of Invasive Fungal Infections during Primary Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Patients in a Tertiary Cancer Center, 2009 to 2011

(2013) Marisa Z. R. Gomes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry

(2012) L. Pagano et al.   CLINICAL INFECTIOUS DISEASES

Antifungal prophylaxis in haematology patients: the role of voriconazole

(2012) Y. Hicheri et al.   CLINICAL MICROBIOLOGY AND INFECTION

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study

(2012) J. Auberger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis

(2012) Andrea Henden et al.   LEUKEMIA & LYMPHOMA

Attributable Hospital Cost and Antifungal Treatment of Invasive Fungal Diseases in High-Risk Hematology Patients: an Economic Modeling Approach

(2011) Michelle R. Ananda-Rajah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period

(2011) M. R. Ananda-Rajah et al.   HAEMATOLOGICA

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases

(2011) Brad Moriyama et al.   MYCOSES

Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients

(2010) Nikolaos G Almyroudis et al.   Expert Review of Anti-Infective Therapy

Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

(2010) Aryun Kim et al.   MYCOSES

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

(2009) Gloria N. Mattiuzzi et al.   SUPPORTIVE CARE IN CANCER

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

(2008) O. A. Cornely et al.   HAEMATOLOGICA